Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review

Alzheimer s & Dementia(2020)10.1002/alz.12175Source: DataRank Database

Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review is a research paper published in Alzheimer s & Dementia (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.99)OA: greenTopics (25)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Yi Chen ORCID,Geoffrey Joyce ORCID,Douglas Barthold ORCID,Paul G Shekelle,Roberta Dı́az Brinton ORCID

Live enrichment

PubMed:33090701 PMC:PMC8112164 OpenAlex:https://openalex.org/W3092619605

National Science Foundation

Grant: R01AG055401

National Science Foundation

Grant: P01AG026572

National Science Foundation

Grant: R37AG053589

National Science Foundation

Grant: R01AG057931

NIA NIH HHS

Grant: P30 AG043073

FWCI

0.99

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

greenLicense: http://onlinelibrary.wiley.com/termsAndConditions#am

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8112164

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112164

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8112164

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12175

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/alz.12175

Fields of Study

Pharmaceutical Practices and Patient OutcomesDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedicineAlzheimer DiseaseChronic DiseaseDementiaDrug-Related Side Effects and Adverse ReactionsHumans

MeSH Terms

Alzheimer DiseaseChronic DiseaseDementiaHumansDrug-Related Side Effects and Adverse Reactions

Keywords

MedicineDrugDiseaseDementiaObservational studyDrug classAlzheimer's diseaseIntensive care medicinePharmacologyInternal medicineDrug Therapies

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Regular proton pump inhibitor use and incident dementia: population-based cohort study

10.6084/m9.figshare.20762918.v1figshare

Additional file 1 of Regular proton pump inhibitor use and incident dementia: population-based cohort study

10.6084/m9.figshare.20762918figshare